The FDA has finalized label revisions for both single ingredient and combination long-acting beta-agonist-containing respiratory medications for the treatment of asthma. This action follows the ...

Long-acting B-agonist (LABA) monotherapy among patients with asthma is rare. Of those with continued LABA monotherapy, most had missed opportunities for therapy change or education. Administrative ...

Arformoterol is the (R,R) enantiomer of formoterol, a long-acting beta2 agonist. It is twice as potent as the racemic mixture. Arformoterol is a bronchodilator that relaxes bronchial smooth muscle ...

regarding the continued availability of single-agent long-acting beta-agonist (LABA) inhalers for use in patients with asthma. She further clarifies that these drugs would remain on the market for ...

Long-acting beta-agonists can be used indefinitely. There is no cutoff in regard to duration. Thus, patients can be on a long-acting beta-agonist for decades if needed. It should be stressed ...

Beta2 (ß2)-agonist medications are a type of inhaled ... Both short-acting ß2-agonists (SABAs) and long-acting ß2-agonists (LABAs) play important—but different—roles in asthma management.

May 5, 2011 — In patients older than 66 years with chronic obstructive pulmonary disease (COPD), initial therapy with long-acting β-agonists appears to be associated with lower mortality rates ...

Long-acting beta agonists (LABAs) were associated with increased risk of asthma-related death, intubation, and hospitalization in a recent meta-analysis of individual patient data conducted by the ...

Research Nester has published a detailed market report on the ‘Global Long-acting Beta-agonists Market’ for the forecast period, i.e., 2022-2031 which includes the ongoing industry innovations ...

This "Long Acting Beta Agonist Market" Report provides detailed information regarding factors influencing the growth of the market, such as drivers, restraints, opportunities, and challenges.